UK Pharma Execs to Help Redesign Drug Pricing Rules Amid Investment Concerns
ByAinvest
Wednesday, Dec 3, 2025 12:28 pm ET1min read
AZN--
GSK--
The UK government is seeking to redesign its drug-pricing system by bringing together senior pharmaceutical executives, including AstraZeneca and GSK, to analyze successors to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG). The initiative aims to address concerns from pharmaceutical manufacturers that the current VPAG structure has hindered investment, and to consider options such as outcomes-based pricing and tying pricing to research and development activity in the UK.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet